X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs DR. REDDYS LAB - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA DR. REDDYS LAB ABBOTT INDIA/
DR. REDDYS LAB
 
P/E (TTM) x 32.3 26.6 121.7% View Chart
P/BV x 8.1 2.7 295.1% View Chart
Dividend Yield % 0.8 1.0 80.3%  

Financials

 ABBOTT INDIA   DR. REDDYS LAB
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
DR. REDDYS LAB
Mar-16
ABBOTT INDIA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs6,0154,383 137.2%   
Low Rs3,7072,750 134.8%   
Sales per share (Unadj.) Rs1,236.9920.1 134.4%  
Earnings per share (Unadj.) Rs122.2126.1 96.9%  
Cash flow per share (Unadj.) Rs129.0183.0 70.5%  
Dividends per share (Unadj.) Rs35.0020.00 175.0%  
Dividend yield (eoy) %0.70.6 128.4%  
Book value per share (Unadj.) Rs521.2685.8 76.0%  
Shares outstanding (eoy) m21.25170.61 12.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.93.9 101.4%   
Avg P/E ratio x39.828.3 140.7%  
P/CF ratio (eoy) x37.719.5 193.4%  
Price / Book Value ratio x9.35.2 179.3%  
Dividend payout %28.615.9 180.6%   
Avg Mkt Cap Rs m103,296608,481 17.0%   
No. of employees `0003.021.7 13.6%   
Total wages/salary Rs m3,37031,874 10.6%   
Avg. sales/employee Rs Th8,891.87,244.4 122.7%   
Avg. wages/employee Rs Th1,140.01,470.9 77.5%   
Avg. net profit/employee Rs Th878.3992.8 88.5%   
INCOME DATA
Net Sales Rs m26,284156,978 16.7%  
Other income Rs m5042,693 18.7%   
Total revenues Rs m26,789159,671 16.8%   
Gross profit Rs m3,66534,587 10.6%  
Depreciation Rs m1449,705 1.5%   
Interest Rs m8824 1.0%   
Profit before tax Rs m4,01726,751 15.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4215,237 27.1%   
Profit after tax Rs m2,59621,514 12.1%  
Gross profit margin %13.922.0 63.3%  
Effective tax rate %35.419.6 180.7%   
Net profit margin %9.913.7 72.1%  
BALANCE SHEET DATA
Current assets Rs m14,446118,201 12.2%   
Current liabilities Rs m4,72568,368 6.9%   
Net working cap to sales %37.031.7 116.5%  
Current ratio x3.11.7 176.8%  
Inventory Days Days5160 85.7%  
Debtors Days Days2097 20.2%  
Net fixed assets Rs m1,11372,265 1.5%   
Share capital Rs m213853 24.9%   
"Free" reserves Rs m10,808111,548 9.7%   
Net worth Rs m11,076117,009 9.5%   
Long term debt Rs m010,690 0.0%   
Total assets Rs m16,241200,104 8.1%  
Interest coverage x497.033.5 1,485.0%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.60.8 206.3%   
Return on assets %16.011.2 143.7%  
Return on equity %23.418.4 127.5%  
Return on capital %36.321.6 168.3%  
Exports to sales %0.646.3 1.3%   
Imports to sales %12.69.0 141.2%   
Exports (fob) Rs m16272,618 0.2%   
Imports (cif) Rs m3,32214,050 23.6%   
Fx inflow Rs m26875,405 0.4%   
Fx outflow Rs m3,92727,115 14.5%   
Net fx Rs m-3,65948,290 -7.6%   
CASH FLOW
From Operations Rs m2,51440,476 6.2%  
From Investments Rs m-800-19,421 4.1%  
From Financial Activity Rs m-803-17,009 4.7%  
Net Cashflow Rs m9124,046 22.5%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 5.4 146.3%  
FIIs % 0.1 35.3 0.3%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.1 15.3 111.8%  
Shareholders   18,270 75,885 24.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare ABBOTT INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Aug 21, 2017 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS